On the public citation graph

Tocilizumab for Treatment of Mechanically Ventilated Patients With COVID-19

https://doi.org/10.1093/cid/ciaa954
0 signed · 529 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/jama.2020.6019openalex-snapshot
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)
inferredcites →https://doi.org/10.1001/jamainternmed.2019.4866openalex-snapshot
Trends in Mortality for Medicare Beneficiaries Treated in the Emergency Department From 2009 to 2016
inferredcites →https://doi.org/10.1001/jamainternmed.2020.0994openalex-snapshot
Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China
inferredcites →https://doi.org/10.1002/jmv.25801openalex-snapshot
Tocilizumab treatment in COVID‐19: A single center experience
inferredcites →https://doi.org/10.1002/sim.6607openalex-snapshot
Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies
inferredcites →https://doi.org/10.1007/s00134-020-05991-xopenalex-snapshot
Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China
inferredcites →https://doi.org/10.1016/0270-0255(86)90088-6openalex-snapshot
A new approach to causal inference in mortality studies with a sustained exposure period—application to control of the healthy worker survivor effect
inferredcites →https://doi.org/10.1016/0898-1221(87)90238-0openalex-snapshot
Addendum to “a new approach to causal inference in mortality studies with a sustained exposure period—application to control of the healthy worker survivor effect”
inferredcites →https://doi.org/10.1016/j.autrev.2020.102537openalex-snapshot
The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease
inferredcites →https://doi.org/10.1016/j.autrev.2020.102564openalex-snapshot
Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia?
inferredcites →https://doi.org/10.1016/j.chest.2020.04.024openalex-snapshot
Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome
inferredcites →https://doi.org/10.1016/j.ejim.2020.05.009openalex-snapshot
Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia
inferredcites →https://doi.org/10.1016/j.ijrobp.2012.02.015openalex-snapshot
Propensity Score-based Comparison of Long-term Outcomes With 3-Dimensional Conformal Radiotherapy vs Intensity-Modulated Radiotherapy for Esophageal Cancer
inferredcites →https://doi.org/10.1016/j.medmal.2020.05.001openalex-snapshot
Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients
inferredcites →https://doi.org/10.1016/s0140-6736(20)30628-0openalex-snapshot
COVID-19: consider cytokine storm syndromes and immunosuppression
inferredcites →https://doi.org/10.1016/s1473-3099(13)70327-xopenalex-snapshot
Open source clinical science for emerging infections
inferredcites →https://doi.org/10.1016/s1473-3099(20)30440-0openalex-snapshot
Global outbreak research: harmony not hegemony
inferredcites →https://doi.org/10.1016/s2665-9913(20)30120-xopenalex-snapshot
The immunology of COVID-19: is immune modulation an option for treatment?
inferredcites →https://doi.org/10.1038/s41375-021-01299-xopenalex-snapshot
Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19
inferredcites →https://doi.org/10.1038/srep32188openalex-snapshot
Effects of IL-1β, IL-6 and IL-8 on erythrocytes, platelets and clot viscoelasticity
inferredcites →https://doi.org/10.1038/srep43829openalex-snapshot
IL-6 ameliorates acute lung injury in influenza virus infection
inferredcites →https://doi.org/10.1056/nejmoa2002032openalex-snapshot
Clinical Characteristics of Coronavirus Disease 2019 in China
inferredcites →https://doi.org/10.1073/pnas.2005615117openalex-snapshot
Effective treatment of severe COVID-19 patients with tocilizumab
inferredcites →https://doi.org/10.1093/aje/kwm324openalex-snapshot
Immortal Time Bias in Pharmacoepidemiology
inferredcites →https://doi.org/10.1097/ede.0b013e3181577511openalex-snapshot
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)
inferredcites →https://doi.org/10.1126/science.abb8925openalex-snapshot
Cytokine release syndrome in severe COVID-19
inferredcites →https://doi.org/10.1136/bmj.m1966openalex-snapshot
Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study
inferredcites →https://doi.org/10.1161/hypertensionaha.118.12286openalex-snapshot
Novel Role of T Cells and IL-6 (Interleukin-6) in Angiotensin II–Induced Microvascular Dysfunction
inferredcites →https://doi.org/10.1177/0962280206074463openalex-snapshot
Multiple imputation of discrete and continuous data by fully conditional specification
inferredcites →https://doi.org/10.1182/blood-2013-02-485623openalex-snapshot
Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy
inferredcites →https://doi.org/10.1378/chest.07-0617openalex-snapshot
Comparison of the Sp o 2 /F io 2 Ratio and the Pa o 2 /F io 2 Ratio in Patients With Acute Lung Injury or ARDS
inferredcites →https://doi.org/10.3389/fmicb.2019.01057openalex-snapshot
The Role of Interleukin 6 During Viral Infections

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4099404openalex-extracted
Antimicrobial Resistance in Patients with COVID-19: A Systematic Review and Meta-Analysis
inferred← citeshttps://doi.org/10.1001/jamainternmed.2020.6557openalex-snapshot
Time to Reassess Tocilizumab’s Role in COVID-19 Pneumonia
inferred← citeshttps://doi.org/10.1002/9781119627784.ch15openalex-snapshot
Accelerating Drug Discovery and Development
inferred← citeshttps://doi.org/10.1002/ccr3.4827openalex-snapshot
Ominous combination: COVID‐19 disease and Candida auris fungemia—Case report and review of the literature
inferred← citeshttps://doi.org/10.1002/cpt.2117openalex-snapshot
COVIDOSE: A Phase II Clinical Trial of Low‐Dose Tocilizumab in the Treatment of Noncritical COVID‐19 Pneumonia
inferred← citeshttps://doi.org/10.1002/cpt.3020openalex-snapshot
Real‐World Evidence to Supplement Randomized Clinical Trials: Tocilizumab for Severe COVID ‐19 Pneumonia vs. a Cohort Receiving Standard of Care
inferred← citeshttps://doi.org/10.1002/dneu.22820openalex-snapshot
Immune cells enhance Zika virus‐mediated neurologic dysfunction in brain of mice with humanized immune systems
inferred← citeshttps://doi.org/10.1002/iid3.587openalex-snapshot
Early use of tocilizumab in solid organ transplant recipients with COVID‐19: A retrospective cohort study in Saudi Arabia
inferred← citeshttps://doi.org/10.1002/jcph.1787openalex-snapshot
Treatment With Tocilizumab for Patients With COVID‐19 Infections: A Case‐Series Study
inferred← citeshttps://doi.org/10.1002/jmv.26471openalex-snapshot
Tocilizumab use in COVID‐19‐associated pneumonia
inferred← citeshttps://doi.org/10.1002/jmv.26509openalex-snapshot
Efficacy of tocilizumab in COVID‐19: A systematic review and meta‐analysis
inferred← citeshttps://doi.org/10.1002/jmv.26674openalex-snapshot
Tocilizumab in hospitalized patients with COVID‐19: Clinical outcomes, inflammatory marker kinetics, and safety
inferred← citeshttps://doi.org/10.1002/jmv.26925openalex-snapshot
The role of teicoplanin in the treatment of SARS‐CoV‐2 infection: A retrospective study in critically ill COVID‐19 patients (Tei‐COVID study)
inferred← citeshttps://doi.org/10.1002/jmv.27102openalex-snapshot
Viral coinfections in COVID‐19
inferred← citeshttps://doi.org/10.1002/jmv.27380openalex-snapshot
Modulation of Covid‐19 cytokine storm by tocilizumab
inferred← citeshttps://doi.org/10.1002/phar.2627openalex-snapshot
Beneficial and harmful outcomes of tocilizumab in severe COVID‐19: A systematic review and meta‐analysis
inferred← citeshttps://doi.org/10.1002/phar.2867openalex-snapshot
Baricitinib versus tocilizumab in critically ill COVID ‐19 patients: A retrospective cohort study
inferred← citeshttps://doi.org/10.1002/rmv.2210openalex-snapshot
Background to new treatments for COVID‐19, including its chronicity, through altering elements of the cytokine storm
inferred← citeshttps://doi.org/10.1007/978-3-031-11363-5_10openalex-snapshot
Interleukin-6 Targeted Agents
inferred← citeshttps://doi.org/10.1007/978-3-031-55254-0_9-1openalex-snapshot
Endothelial Control of the Inflammatory Process
inferred← citeshttps://doi.org/10.1007/978-981-15-8681-1_5openalex-snapshot
Therapeutic Approach to Coronavirus Disease
inferred← citeshttps://doi.org/10.1007/978-981-97-4909-6_17openalex-snapshot
Drug-Resistance Patterns in Opportunistic Aspergilli: A Molecular Perspective
inferred← citeshttps://doi.org/10.1007/978-981-99-2718-0_15openalex-snapshot
Immunological Interventions for the Management of Coronavirus Disease 2019 (COVID-19)
inferred← citeshttps://doi.org/10.1007/978-981-99-9577-6_12openalex-snapshot
COVID-19 Infection in Obstetrical Patients Requiring Intensive Care: An Update
inferred← citeshttps://doi.org/10.1007/s00005-023-00673-0openalex-snapshot
Immunity in SARS-CoV-2 Infection: Clarity or Mystery? A Broader Perspective in the Third Year of a Worldwide Pandemic
inferred← citeshttps://doi.org/10.1007/s00011-021-01507-5openalex-snapshot
The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study
inferred← citeshttps://doi.org/10.1007/s00134-021-06346-wopenalex-snapshot
COVID-19 increased the risk of ICU-acquired bloodstream infections: a case–cohort study from the multicentric OUTCOMEREA network
inferred← citeshttps://doi.org/10.1007/s00134-021-06416-zopenalex-snapshot
Tocilizumab in COVID-19: a meta-analysis, trial sequential analysis, and meta-regression of randomized-controlled trials
inferred← citeshttps://doi.org/10.1007/s00228-023-03517-0openalex-snapshot
Translatability scoring in prospective and retrospective COVID drug development cases
inferred← citeshttps://doi.org/10.1007/s00540-020-02825-4openalex-snapshot
COVID-19: review of case reports
inferred← citeshttps://doi.org/10.1007/s10238-020-00671-yopenalex-snapshot
Emerging treatment strategies for COVID-19 infection
inferred← citeshttps://doi.org/10.1007/s10787-021-00811-0openalex-snapshot
Brief review of the mRNA vaccines COVID-19
inferred← citeshttps://doi.org/10.1007/s10875-020-00911-6openalex-snapshot
Tocilizumab for Severe Worsening COVID-19 Pneumonia: a Propensity Score Analysis
inferred← citeshttps://doi.org/10.1007/s11046-021-00564-yopenalex-snapshot
COVID-19-Associated Pulmonary Aspergillosis at an Academic Medical Center in the Midwestern United States
inferred← citeshttps://doi.org/10.1007/s11739-020-02600-zopenalex-snapshot
Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study
inferred← citeshttps://doi.org/10.1007/s11739-021-02690-3openalex-snapshot
Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID‑19 pneumonia and moderate hyperinflammation. A retrospective cohort study: reply
inferred← citeshttps://doi.org/10.1007/s11739-022-02957-3openalex-snapshot
Use of antibiotics in respiratory viral infections
inferred← citeshttps://doi.org/10.1007/s11926-020-00971-yopenalex-snapshot
COVID-19: What Do Rheumatologists Need to Know?
inferred← citeshttps://doi.org/10.1007/s12519-024-00798-yopenalex-snapshot
Treatment of multisystem inflammatory syndrome in children
inferred← citeshttps://doi.org/10.1007/s15010-021-01643-4openalex-snapshot
Multidrug-resistant Acinetobacter baumannii infections in COVID-19 patients hospitalized in intensive care unit
inferred← citeshttps://doi.org/10.1007/s40121-020-00373-8openalex-snapshot
Combination of Tocilizumab and Steroids to Improve Mortality in Patients with Severe COVID-19 Infection: A Spanish, Multicenter, Cohort Study
inferred← citeshttps://doi.org/10.1007/s40121-021-00477-9openalex-snapshot
Impact of Inflammatory Response Modifiers on the Incidence of Hospital-Acquired Infections in Patients with COVID-19
inferred← citeshttps://doi.org/10.1007/s40121-021-00483-xopenalex-snapshot
Efficacy and Safety of Tocilizumab Treatment COVID-19 Patients: A Case-Control Study and Meta-Analysis
inferred← citeshttps://doi.org/10.1007/s40121-021-00486-8openalex-snapshot
Epidemiology and Incidence of COVID-19-Associated Pulmonary Aspergillosis (CAPA) in a Greek Tertiary Care Academic Reference Hospital
inferred← citeshttps://doi.org/10.1007/s40199-021-00430-8openalex-snapshot
Comparing the efficacy of tocilizumab with corticosteroid therapy in treating COVID-19 patients: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1007/s40265-022-01803-2openalex-snapshot
Should We Interfere with the Interleukin-6 Receptor During COVID-19: What Do We Know So Far?
inferred← citeshttps://doi.org/10.1007/s40472-020-00306-xopenalex-snapshot
Immunomodulatory Therapies for COVID-19 in Solid Organ Transplant Recipients
inferred← citeshttps://doi.org/10.1016/b978-0-443-32930-2.00010-6openalex-snapshot
Diagnosis and treatment
inferred← citeshttps://doi.org/10.1016/j.acci.2020.09.004openalex-snapshot
Actualización de la Declaración de consenso en medicina critica para la atención multidisciplinaria del paciente con sospecha o confirmación diagnóstica de COVID-19
inferred← citeshttps://doi.org/10.1016/j.ajpath.2020.08.009openalex-snapshot
Immunopathology of Hyperinflammation in COVID-19
inferred← citeshttps://doi.org/10.1016/j.amsu.2020.10.061openalex-snapshot
Tocilizumab in the treatment of rapidly evolving COVID-19 pneumonia and multifaceted critical illness: A retrospective case series
inferred← citeshttps://doi.org/10.1016/j.anai.2021.02.013openalex-snapshot
Asthma in patients with coronavirus disease 2019
inferred← citeshttps://doi.org/10.1016/j.aqrep.2025.102948openalex-snapshot
Emerging anthropozoonotic threat in amphibian aquaculture: First report of Trichosporon asahii-induced epidemic with cross-species virulence
inferred← citeshttps://doi.org/10.1016/j.bbrc.2020.11.084openalex-snapshot
Immunomodulation for the management of severe SARS-CoV2 infections. State of the art and review of the literature
inferred← citeshttps://doi.org/10.1016/j.bcp.2020.114184openalex-snapshot
COVID-19: An overview of the current pharmacological interventions, vaccines, and clinical trials
inferred← citeshttps://doi.org/10.1016/j.bcp.2022.114909openalex-snapshot
Vascular endotheliitis associated with infections: Its pathogenetic role and therapeutic implication
inferred← citeshttps://doi.org/10.1016/j.biopha.2020.110698openalex-snapshot
The role of Interleukin 6 inhibitors in therapy of severe COVID-19
inferred← citeshttps://doi.org/10.1016/j.biopha.2020.110825openalex-snapshot
Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size
inferred← citeshttps://doi.org/10.1016/j.biopha.2022.114082openalex-snapshot
Humulus lupus extract rich in xanthohumol improves the clinical course in critically ill COVID-19 patients
inferred← citeshttps://doi.org/10.1016/j.biopha.2024.117177openalex-snapshot
The interplay between cytokines, inflammation, and antioxidants: mechanistic insights and therapeutic potentials of various antioxidants and anti-cytokine compounds
inferred← citeshttps://doi.org/10.1016/j.ccc.2022.01.003openalex-snapshot
COVID-19 in the Critically Ill Pregnant Patient
inferred← citeshttps://doi.org/10.1016/j.ccell.2020.09.018openalex-snapshot
COVID-19 and Cancer: Current Challenges and Perspectives
inferred← citeshttps://doi.org/10.1016/j.clim.2022.109022openalex-snapshot
Anti-inflammatory and immune therapy in severe coronavirus disease 2019 (COVID-19) patients: An update
inferred← citeshttps://doi.org/10.1016/j.cmi.2020.10.036openalex-snapshot
Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1016/j.cmi.2021.11.008openalex-snapshot
Predictors and microbiology of respiratory and bloodstream bacterial infection in patients with COVID-19: living rapid review update and meta-regression
inferred← citeshttps://doi.org/10.1016/j.cpcardiol.2022.101250openalex-snapshot
Molecular Determinants, Clinical Manifestations and Effects of Immunization on Cardiovascular Health During COVID-19 Pandemic Era - A Review
inferred← citeshttps://doi.org/10.1016/j.crmicr.2024.100220openalex-snapshot
Accelerating the understanding of Aspergillus terreus: Epidemiology, physiology, immunology and advances
inferred← citeshttps://doi.org/10.1016/j.cyto.2020.155393openalex-snapshot
Experience of using tocilizumab for treatment in Indonesian patients with severe COVID-19
inferred← citeshttps://doi.org/10.1016/j.cyto.2023.156420openalex-snapshot
Cytokine storm in COVID-19 and malaria: Annals of pro-inflammatory cytokines
inferred← citeshttps://doi.org/10.1016/j.douler.2023.07.003openalex-snapshot
Inflammation aiguë, inflammation chronique – 2e partie : IL-6 et COVID-19
inferred← citeshttps://doi.org/10.1016/j.eclinm.2020.100630openalex-snapshot
Ethnicity and clinical outcomes in COVID-19: A systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1016/j.eimc.2022.02.002openalex-snapshot
Coinfection and superinfection in SARS-CoV-2 pneumonia. Two underestimated threats. The need of empirical treatment under debate
inferred← citeshttps://doi.org/10.1016/j.eimce.2022.02.011openalex-snapshot
Coinfection and superinfection in SARS-CoV-2 pneumonia. Two underestimated threats. The need of empirical treatment under debate
inferred← citeshttps://doi.org/10.1016/j.ejca.2020.09.009openalex-snapshot
Evidence-based management of COVID-19 in cancer patients: Guideline by the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)
inferred← citeshttps://doi.org/10.1016/j.ejim.2020.10.020openalex-snapshot
Interleukin-6 receptor blockade with subcutaneous tocilizumab improves coagulation activity in patients with COVID-19
inferred← citeshttps://doi.org/10.1016/j.fbr.2021.09.003openalex-snapshot
The rise in cases of mucormycosis, candidiasis and aspergillosis amidst COVID19
inferred← citeshttps://doi.org/10.1016/j.heliyon.2024.e35988openalex-snapshot
Repurposing existing drugs for the treatment ofCOVID-19/SARS-CoV-2: A review of pharmacological effects and mechanism of action
inferred← citeshttps://doi.org/10.1016/j.hrtlng.2022.06.024openalex-snapshot
“Ventilator-free days” composite outcome in patients with SARS-CoV-2 infection treated with tocilizumab: A retrospective competing risk analysis
inferred← citeshttps://doi.org/10.1016/j.idcr.2021.e01067openalex-snapshot
Recovery does not always signal the end of the battle: A case of post SARS-CoV-2 multisystem inflammatory syndrome in an adult
inferred← citeshttps://doi.org/10.1016/j.idcr.2021.e01244openalex-snapshot
Trichosporon asahii fungemia and COVID-19 co-infection: An emerging fungal pathogen; case report and review of the literature
inferred← citeshttps://doi.org/10.1016/j.ijantimicag.2021.106334openalex-snapshot
Therapeutic plasma exchange in patients with life-threatening COVID-19: a randomised controlled clinical trial
inferred← citeshttps://doi.org/10.1016/j.ijid.2020.08.024openalex-snapshot
Impact of tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients
inferred← citeshttps://doi.org/10.1016/j.ijid.2020.09.1447openalex-snapshot
Tocilizumab therapy for COVID-19: A comparison of subcutaneous and intravenous therapies
inferred← citeshttps://doi.org/10.1016/j.ijid.2020.10.045openalex-snapshot
Compassionate use of tocilizumab in severe SARS-CoV2 pneumonia
inferred← citeshttps://doi.org/10.1016/j.ijid.2020.12.021openalex-snapshot
Tocilizumab in the treatment of critical COVID-19 pneumonia: A retrospective cohort study of mechanically ventilated patients
inferred← citeshttps://doi.org/10.1016/j.ijid.2021.02.057openalex-snapshot
Tocilizumab treatment in critically ill patients with COVID-19: A retrospective observational study
inferred← citeshttps://doi.org/10.1016/j.ijid.2022.01.040openalex-snapshot
Analysis of the factors predicting clinical response to tocilizumab therapy in patients with severe COVID-19
inferred← citeshttps://doi.org/10.1016/j.ijid.2022.01.048openalex-snapshot
Treatment with Tocilizumab in Adult Patients with Moderate to Critical COVID‐19 Pneumonia: A Single‐Center Retrospective Study
inferred← citeshttps://doi.org/10.1016/j.immuni.2020.12.001openalex-snapshot
The persistence of interleukin-6 is regulated by a blood buffer system derived from dendritic cells
inferred← citeshttps://doi.org/10.1016/j.intimp.2020.107102openalex-snapshot
Subcutaneous tocilizumab in adults with severe and critical COVID-19: A prospective open-label uncontrolled multicenter trial
inferred← citeshttps://doi.org/10.1016/j.intimp.2022.108536openalex-snapshot
An updated overview of recent advances, challenges, and clinical considerations of IL-6 signaling blockade in severe coronavirus disease 2019 (COVID-19)
inferred← citeshttps://doi.org/10.1016/j.jaut.2020.102580openalex-snapshot
A multidisciplinary registry of patients with autoimmune and immune-mediated diseases with symptomatic COVID-19 from a single center
inferred← citeshttps://doi.org/10.1016/j.jcrc.2021.08.007openalex-snapshot
Single versus multiple doses of Tocilizumab in critically ill patients with coronavirus disease 2019 (COVID-19): A two-center, retrospective cohort study
inferred← citeshttps://doi.org/10.1016/j.jfma.2022.09.014openalex-snapshot
The COVIDTW study: Clinical predictors of COVID-19 mortality and a novel AI prognostic model using chest X-ray
inferred← citeshttps://doi.org/10.1016/j.jiac.2024.09.013openalex-snapshot
Tocilizumab in combination with standard of care in patients with severe COVID-19 pneumonia: Efficacy and safety from a phase 3 clinical trial in Japan
inferred← citeshttps://doi.org/10.1016/j.jiph.2021.06.004openalex-snapshot
Interleukin-6 (IL-6) inhibitors as therapeutic agents for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1016/j.jiph.2021.10.024openalex-snapshot
Efficacy of the early treatment with tocilizumab-hydroxychloroquine and tocilizumab-remdesivir in severe COVID-19 Patients
inferred← citeshttps://doi.org/10.1016/j.jiph.2021.12.007openalex-snapshot
Response to the letter to the editor
inferred← citeshttps://doi.org/10.1016/j.jmb.2021.166945openalex-snapshot
Platforms for Personalized Polytherapeutics Discovery in COVID-19
inferred← citeshttps://doi.org/10.1016/j.jtho.2020.12.014openalex-snapshot
Coronavirus 2019 Infectious Disease Epidemic: Where We Are, What Can Be Done and Hope For
inferred← citeshttps://doi.org/10.1016/j.kint.2020.10.004openalex-snapshot
COVID-19 infection in kidney transplant recipients at the epicenter of pandemics
inferred← citeshttps://doi.org/10.1016/j.lfs.2020.118097openalex-snapshot
The bio-mission of interleukin-6 in the pathogenesis of COVID-19: A brief look at potential therapeutic tactics
inferred← citeshttps://doi.org/10.1016/j.lfs.2021.119201openalex-snapshot
COVID-19, cytokines, inflammation, and spices: How are they related?
inferred← citeshttps://doi.org/10.1016/j.medcle.2020.12.010openalex-snapshot
Tocilizumab in patients infected by SARS-CoV2
inferred← citeshttps://doi.org/10.1016/j.medcle.2021.06.025openalex-snapshot
Tocilizumab therapy in SARS-CoV-2 pneumonia: A matched retrospective cohort analysis
inferred← citeshttps://doi.org/10.1016/j.medcli.2020.12.003openalex-snapshot
Tocilizumab en el paciente con COVID-19
inferred← citeshttps://doi.org/10.1016/j.medcli.2021.06.014openalex-snapshot
Tocilizumab therapy in SARS-CoV-2 pneumonia: A matched retrospective cohort analysis
inferred← citeshttps://doi.org/10.1016/j.medin.2021.02.013openalex-snapshot
Predictive factors of six-week mortality in critically ill patients with SARS-CoV-2: A multicenter prospective study
inferred← citeshttps://doi.org/10.1016/j.medin.2021.04.007openalex-snapshot
Manejo de las complicaciones infecciosas asociadas con la infección por coronavirus en pacientes graves ingresados en UCI
inferred← citeshttps://doi.org/10.1016/j.medine.2021.02.008openalex-snapshot
Predictive factors of six-week mortality in critically ill patients with SARS-CoV-2: A multicenter prospective study
inferred← citeshttps://doi.org/10.1016/j.medine.2021.08.013openalex-snapshot
Management of infectious complications associated with coronavirus infection in severe patients admitted to ICU
inferred← citeshttps://doi.org/10.1016/j.mehy.2020.110394openalex-snapshot
Hypothesis: Alpha-1-antitrypsin is a promising treatment option for COVID-19
inferred← citeshttps://doi.org/10.1016/j.mmr.2026.100014openalex-snapshot
Pathophysiology-guided biomarkers and therapeutics for precision trauma medicine in polytrauma with musculoskeletal injuries
inferred← citeshttps://doi.org/10.1016/j.nut.2020.110948openalex-snapshot
Vitamin C as prophylaxis and adjunctive medical treatment for COVID-19?
inferred← citeshttps://doi.org/10.1016/j.onehlt.2021.100214openalex-snapshot
Matched cohort study on the efficacy of tocilizumab in patients with COVID-19
inferred← citeshttps://doi.org/10.1016/j.pmedr.2023.102276openalex-snapshot
Efficacy and safety of interleukin-6 receptor antagonists in adult patients admitted to intensive care unit with COVID-19: A systematic review and meta-analysis of randomized controlled trials
inferred← citeshttps://doi.org/10.1016/j.pulmoe.2020.07.003openalex-snapshot
Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review
inferred← citeshttps://doi.org/10.1016/j.rmr.2022.11.085openalex-snapshot
Inhibiteurs du récepteur de l’IL-6 dans le traitement de la COVID-19 : que savons-nous ?
inferred← citeshttps://doi.org/10.1016/j.rmr.2023.09.005openalex-snapshot
Prise en charge ventilatoire de l’insuffisance respiratoire aiguë à SARS-CoV-2
inferred← citeshttps://doi.org/10.1016/j.thromres.2026.109723openalex-snapshot
Inhibition of inflammation reduces hypofibrinolysis in severe COVID-19: A nested case-control study within the MaastrICCht cohort
inferred← citeshttps://doi.org/10.1016/j.tips.2020.07.004openalex-snapshot
Fruitful Neutralizing Antibody Pipeline Brings Hope To Defeat SARS-Cov-2
inferred← citeshttps://doi.org/10.1016/j.transproceed.2021.01.002openalex-snapshot
Coronavirus Disease 2019 in Kidney Transplant Recipients: Single-Center Experience and Case-Control Study
inferred← citeshttps://doi.org/10.1016/j.trre.2023.100788openalex-snapshot
Executive summary of the consensus statement of the group for the study of infection in transplantation and other immunocompromised host (GESITRA-IC) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) on the treatment of SARS-CoV-2 infection in solid organ transplant…
inferred← citeshttps://doi.org/10.1016/s1473-3099(20)30847-1openalex-snapshot
Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance
inferred← citeshttps://doi.org/10.1016/s2213-2600(21)00103-xopenalex-snapshot
Interleukin-6: obstacles to targeting a complex cytokine in critical illness
inferred← citeshttps://doi.org/10.1016/s2666-5247(22)00355-xopenalex-snapshot
Antimicrobial resistance in patients with COVID-19: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1017/ice.2021.227openalex-snapshot
Surveillance of adverse drug events associated with tocilizumab in hospitalized veterans with coronavirus disease 2019 (COVID-19) to inform patient safety and pandemic preparedness
inferred← citeshttps://doi.org/10.1017/ice.2021.341openalex-snapshot
Risk factors and outcomes associated with community-onset and hospital-acquired coinfection in patients hospitalized for coronavirus disease 2019 (COVID-19): A multihospital cohort study
inferred← citeshttps://doi.org/10.1021/acs.jpcb.4c07920openalex-snapshot
In Silico Discovery of SARS-CoV-2 Main Protease Inhibitors Using Docking, Molecular Dynamics, and Fragment Molecular Orbital Calculations
inferred← citeshttps://doi.org/10.1021/acsinfecdis.0c00343openalex-snapshot
Old Drugs for a New Virus: Repurposed Approaches for Combating COVID-19
inferred← citeshttps://doi.org/10.1038/s41375-021-01264-8openalex-snapshot
Systematic review and meta-analysis of tocilizumab in persons with coronavirus disease-2019 (COVID-19)
inferred← citeshttps://doi.org/10.1038/s41551-020-0579-9openalex-snapshot
COVID-19 remedies
inferred← citeshttps://doi.org/10.1038/s41556-021-00681-2openalex-snapshot
Single-cell RNA sequencing of blood antigen-presenting cells in severe COVID-19 reveals multi-process defects in antiviral immunity
inferred← citeshttps://doi.org/10.1038/s41598-020-78710-7openalex-snapshot
Increased interleukin-6 and macrophage chemoattractant protein-1 are associated with respiratory failure in COVID-19
inferred← citeshttps://doi.org/10.1038/s41598-021-01462-5openalex-snapshot
D-dimer, disease severity, and deaths (3D-study) in patients with COVID-19: a systematic review and meta-analysis of 100 studies
inferred← citeshttps://doi.org/10.1038/s41598-021-99291-zopenalex-snapshot
Tocilizumab reduces COVID-19 mortality and pathology in a dose and timing-dependent fashion: a multi-centric study
inferred← citeshttps://doi.org/10.1038/s41598-024-71912-3openalex-snapshot
The usage of immunosuppressant agents and secondary infections in patients with COVID-19 in the intensive care unit: a retrospective study
inferred← citeshttps://doi.org/10.1038/s41598-025-08638-3openalex-snapshot
Tocilizumab as a targeted immunomodulatory therapy in the management of severe respiratory illnesses: a multicenter cohort study of COVID-19 patients
inferred← citeshttps://doi.org/10.1039/d3sc03438kopenalex-snapshot
A living neutrophil Biorobot synergistically blocks multifaceted inflammatory pathways in macrophages to effectively neutralize cytokine storm
inferred← citeshttps://doi.org/10.1055/a-1336-2371openalex-snapshot
Efficacy and Safety of Tocilizumab for Coronavirus Disease 2019 (Covid-19) Patients: A Systematic Review and Meta-analysis
inferred← citeshttps://doi.org/10.1056/nejme2032071openalex-snapshot
Tocilizumab for Covid-19 — The Ongoing Search for Effective Therapies
inferred← citeshttps://doi.org/10.1056/nejmoa2028700openalex-snapshot
Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia
inferred← citeshttps://doi.org/10.1056/nejmoa2028836openalex-snapshot
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
inferred← citeshttps://doi.org/10.1056/nejmoa2100433openalex-snapshot
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19
inferred← citeshttps://doi.org/10.1071/ma20058openalex-snapshot
Therapeutics for COVID-19: established and in development
inferred← citeshttps://doi.org/10.1071/ma20058_coopenalex-snapshot
Corrigendum to : Therapeutics for COVID-19: established and in development
inferred← citeshttps://doi.org/10.1071/mav41n4openalex-snapshot
Volume 41 Number 4
inferred← citeshttps://doi.org/10.1080/10428194.2020.1869963openalex-snapshot
Severe COVID-19 infection in a patient with paroxysmal nocturnal hemoglobinuria on eculizumab therapy
inferred← citeshttps://doi.org/10.1080/13543784.2021.1901883openalex-snapshot
The time to offer treatments for COVID-19
inferred← citeshttps://doi.org/10.1080/14712598.2021.1905794openalex-snapshot
A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19
inferred← citeshttps://doi.org/10.1080/14740338.2021.1946513openalex-snapshot
Tocilizumab in COVID-19: a study of adverse drug events reported in the WHO database
inferred← citeshttps://doi.org/10.1080/14787210.2020.1813024openalex-snapshot
Azithromycin in the treatment of COVID-19: a review
inferred← citeshttps://doi.org/10.1080/14787210.2022.2046462openalex-snapshot
Tocilizumab effectiveness in mechanically ventilated COVID-19 patients (T-MVC-19 Study): a multicenter real-world evidence
inferred← citeshttps://doi.org/10.1080/14787210.2023.2226867openalex-snapshot
Tocilizumab for the treatment of COVID-19
inferred← citeshttps://doi.org/10.1080/14787210.2026.2682316openalex-snapshot
Superinfection risk in critically ill patients with severe COVID-19: a retrospective analysis of pulse steroid therapy with and without tocilizumab
inferred← citeshttps://doi.org/10.1080/14787210.2026.2725738openalex-snapshot
Association of tocilizumab use with mortality and clinical outcomes in critically ill patients followed in the intensive care unit for COVID-19 pneumonia: a single-center retrospective cohort study
inferred← citeshttps://doi.org/10.1080/17434440.2021.1915764openalex-snapshot
Mortality in mechanically ventilated patients with COVID-19: a systematic review
inferred← citeshttps://doi.org/10.1080/1744666x.2021.1908128openalex-snapshot
Efficacy and safety of Tocilizumab in severe and critical COVID-19: A Systematic Review and Meta-Analysis
inferred← citeshttps://doi.org/10.1080/17512433.2021.1875819openalex-snapshot
Clinical course of severe patients with COVID-19 treated with tocilizumab: report from a cohort study in Spain
inferred← citeshttps://doi.org/10.1080/17512433.2021.1949286openalex-snapshot
Tocilizumab for the treatment of non‐critical COVID‐19 pneumonia: an overview of the rationale and clinical evidence to date
inferred← citeshttps://doi.org/10.1080/19420862.2022.2031483openalex-snapshot
Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming?
inferred← citeshttps://doi.org/10.1089/jir.2022.0185openalex-snapshot
The Role of Inflammatory Cytokines (Interleukin-1 and Interleukin-6) as a Potential Biomarker in the Different Stages of COVID-19 (Mild, Severe, and Critical)
inferred← citeshttps://doi.org/10.1089/jir.2022.0210openalex-snapshot
Comparison of the Antiviral Activity of Remdesivir, Chloroquine, and Interferon-β as Single or Dual Agents Against the Human Beta-Coronavirus OC43
inferred← citeshttps://doi.org/10.1093/cid/ciaa1079openalex-snapshot
Are All Patients with Cancer at Heightened Risk for Severe Coronavirus Disease 2019 (COVID-19)?
inferred← citeshttps://doi.org/10.1093/cid/ciaa1133openalex-snapshot
To Toci or Not to Toci for Coronavirus Disease 2019 (COVID-19): Is That Still the Question?
inferred← citeshttps://doi.org/10.1093/cid/ciaa1239openalex-snapshot
Empiric Antibacterial Therapy and Community-onset Bacterial Coinfection in Patients Hospitalized With Coronavirus Disease 2019 (COVID-19): A Multi-hospital Cohort Study
inferred← citeshttps://doi.org/10.1093/cid/ciaa1284openalex-snapshot
Efficacy of Tocilizumab For Treatment of Severe COVID-19 Pneumonia: More Evidence Is Needed
inferred← citeshttps://doi.org/10.1093/cid/ciaa1287openalex-snapshot
Reply to Olivera and Mallat
inferred← citeshttps://doi.org/10.1093/cid/ciaa1445openalex-snapshot
Decreased Mortality in Coronavirus Disease 2019 Patients Treated With Tocilizumab: A Rapid Systematic Review and Meta-analysis of Observational Studies
inferred← citeshttps://doi.org/10.1093/cid/ciaa1654openalex-snapshot
COVID-19—Lessons Learned and Questions Remaining
inferred← citeshttps://doi.org/10.1093/cid/ciaa1735openalex-snapshot
The Misleading “Pooled Effect Estimate” of Crude Data from Observational Studies at Critical Risk of Bias: The Case of Tocilizumab in Coronavirus Disease 2019 (COVID-19)
inferred← citeshttps://doi.org/10.1093/cid/ciaa1736openalex-snapshot
Reply to Tleyjeh
inferred← citeshttps://doi.org/10.1093/cid/ciaa1759openalex-snapshot
Immunomodulation as Treatment for Severe Coronavirus Disease 2019: A Systematic Review of Current Modalities and Future Directions
inferred← citeshttps://doi.org/10.1093/cid/ciac724openalex-snapshot
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (September 2022)
inferred← citeshttps://doi.org/10.1093/cid/ciad160openalex-snapshot
Infectious Complications of Lung Transplant for Coronavirus Disease 2019–Associated Lung Injury: A Single-Center Case-Control Cohort Study
inferred← citeshttps://doi.org/10.1093/eurheartj/ehaa623openalex-snapshot
COVID-19 is, in the end, an endothelial disease
inferred← citeshttps://doi.org/10.1093/infdis/jiaa717openalex-snapshot
The Effect of IL-6 Inhibitors on Mortality Among Hospitalized COVID-19 Patients: A Multicenter Study
inferred← citeshttps://doi.org/10.1093/infdis/jiad195openalex-snapshot
Molnupiravir Use and 30-Day Hospitalizations or Death in a Previously Uninfected Nonhospitalized High-risk Population With COVID-19
inferred← citeshttps://doi.org/10.1093/jac/dkaa530openalex-snapshot
Predictors of hospital-acquired bacterial and fungal superinfections in COVID-19: a prospective observational study
inferred← citeshttps://doi.org/10.1093/jac/dkad054openalex-snapshot
The use of prophylactic nebulized liposomal amphotericin B to reduce the risk of CAPA in mechanically ventilated COVID-19 patients on ICU in a large UK tertiary teaching hospital trust
inferred← citeshttps://doi.org/10.1093/jacamr/dlae013openalex-snapshot
Antimicrobial consumption in an acute NHS Trust during the COVID-19 pandemic: intervention time series analysis
inferred← citeshttps://doi.org/10.1093/jpids/piaa098openalex-snapshot
Multidisciplinary Guidance Regarding the Use of Immunomodulatory Therapies for Acute Coronavirus Disease 2019 in Pediatric Patients
inferred← citeshttps://doi.org/10.1093/mmy/myad054openalex-snapshot
Assessing the safety profile of voriconazole use in suspected COVID-19-associated pulmonary aspergillosis–a two-centre observational study
inferred← citeshttps://doi.org/10.1093/ofid/ofaa598openalex-snapshot
Tocilizumab for the Treatment of COVID-19 Among Hospitalized Patients: A Matched Retrospective Cohort Analysis
inferred← citeshttps://doi.org/10.1093/ofid/ofaa616openalex-snapshot
Real-World Inpatient Use of Medications Repurposed for Coronavirus Disease 2019 in United States Hospitals, March–May 2020
inferred← citeshttps://doi.org/10.1093/ofid/ofab201openalex-snapshot
Characterization of Bacterial and Fungal Infections in Hospitalized Patients With Coronavirus Disease 2019 and Factors Associated With Health Care-Associated Infections
inferred← citeshttps://doi.org/10.1093/ofid/ofab339openalex-snapshot
Hospital-Acquired Bloodstream Infections in Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 Infection (Coronavirus Disease 2019): Association With Immunosuppressive Therapies
inferred← citeshttps://doi.org/10.1093/ofid/ofab452openalex-snapshot
A High Frequency of Candida auris Blood Stream Infections in Coronavirus Disease 2019 Patients Admitted to Intensive Care Units, Northwestern India: A Case Control Study
inferred← citeshttps://doi.org/10.1093/ofid/ofac083openalex-snapshot
Pathogen Species Is Associated With Mortality in Nosocomial Bloodstream Infection in Patients With COVID-19
inferred← citeshttps://doi.org/10.1097/cce.0000000000000203openalex-snapshot
The Association of Inflammatory Cytokines in the Pulmonary Pathophysiology of Respiratory Failure in Critically Ill Patients With Coronavirus Disease 2019
inferred← citeshttps://doi.org/10.1097/cce.0000000000000232openalex-snapshot
Clinical Outcomes Following Tocilizumab Administration in Mechanically Ventilated Coronavirus Disease 2019 Patients
inferred← citeshttps://doi.org/10.1097/cce.0000000000000283openalex-snapshot
A Propensity-Matched Cohort Study of Tocilizumab in Patients With Coronavirus Disease 2019
inferred← citeshttps://doi.org/10.1097/cce.0000000000000327openalex-snapshot
Tocilizumab in Coronavirus Disease 2019-Related Critical Illness: A Propensity Matched Analysis
inferred← citeshttps://doi.org/10.1097/cce.0000000000000395openalex-snapshot
Early Tocilizumab Dosing Is Associated With Improved Survival in Critically Ill Patients Infected With Severe Acute Respiratory Syndrome Coronavirus-2
inferred← citeshttps://doi.org/10.1097/cce.0000000000000492openalex-snapshot
Pharmacotherapy in Coronavirus Disease 2019 and Risk of Secondary Infections: A Single-Center Case Series and Narrative Review
inferred← citeshttps://doi.org/10.1097/ipc.0000000000000940openalex-snapshot
Tocilizumab Treatment in COVID-19–induced Cytokine Release Syndrome
inferred← citeshttps://doi.org/10.1097/jcma.0000000000000969openalex-snapshot
Elevated serum levels of T-cell immunoglobulin and mucin-domain containing molecule 3 in patients with systemic inflammation following COVID-19 vaccination
inferred← citeshttps://doi.org/10.1097/mat.0000000000001707openalex-snapshot
Tocilizumab Accelerates Recovery in Patients With Severe COVID-19 Pneumonia on Venovenous Extracorporeal Membrane Oxygenation
inferred← citeshttps://doi.org/10.1097/mcp.0000000000000766openalex-snapshot
Coronavirus disease 2019 management
inferred← citeshttps://doi.org/10.1097/md.0000000000025634openalex-snapshot
Major determinants of death in patients hospitalized with COVID-19 during the first epidemic wave in Madrid, Spain
showing the first 200 of 497
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.